7/8 May 2024
In December 2017, the Food and Drug Administration's Center for Biologics Evaluation and Research published an updated version of their "Guidance for Industry Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry" for immediate implementation. This update of the original guideline published in 2010 includes the following revisions:
With this update, the FDA supplies new recommendations for blood and plasma establishments, fractionators and test laboratories for the testing of individual and pool donations regarding HIV-1 and HCV. It is part of FDA's activity to strengthen the overlapping safeguards that protect patients from unsuitable blood and blood products and should support the establishments in questions of testing, product disposition, donor deferral, donor notification, donor reentry and lookback.
Further details can be found directly in the revised guideline "Guidance for Industry Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry".